SCHEMBL30748935

SCHEMBL30748935

CC1(C)C(=O)N(c2ccc(N3CCOCC3)cc2)c2nc(CO[Si](C)(C)C(C)(C)C)nc(N)c21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGXT P21549 1/20 0.37
XDH P47989 1/20 0.34
DHFR P00374 2/20 0.32
LGMN Q99538 3/20 0.32
TLR7 Q9NYK1 1/20 0.32
ALDH1A1 P00352 3/20 0.32
GAA P10253 2/20 0.32
USP2 O75604 1/20 0.32
DGAT1 O75907 1/20 0.32
KMT2A Q03164 2/20 0.31
GLA P06280 1/20 0.31
TSHR P16473 1/20 0.31
MRGPRX4 Q96LA9 1/20 0.31
BRD4 O60885 1/20 0.31
PLK1 P53350 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
MAPT P10636 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748783 0.90 AGXT (0.34) AGXTALDH1A1GAAUSP2KMT2A
SCHEMBL31691354 0.88 AGXT (0.33) AGXTALDH1A1GAAUSP2KMT2A
SCHEMBL30749058 0.87 ADORA3 (0.36) AGXTALDH1A1GAAKMT2AMRGPRX4
SCHEMBL30748976 0.86 SYK (0.36) AGXTALDH1A1TSHRMRGPRX4KDM4E
SCHEMBL30748860 0.85 RAD52 (0.33) AGXTTLR7ALDH1A1BRD4MAPT
SCHEMBL30749048 0.84 NTRK1 (0.31) AGXTALDH1A1MAPTMAPK1
SCHEMBL30748754 0.83 XDH (0.36) AGXTXDHDHFRLGMNTLR7
SCHEMBL31691365 0.80 MAPT (0.33) AGXTALDH1A1MAPT
SCHEMBL30748750 0.80 MTOR (0.36) ALDH1A1GAAKDM4E
SCHEMBL31691363 0.79 MEN1 (0.31) AGXTALDH1A1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT AGXT 955/4885XDH 404/4885DHFR 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.